New combo therapy aims to shrink rectal tumors without surgery

NCT ID NCT07469306

First seen Apr 10, 2026 · Last updated Jun 10, 2026 · Updated 11 times

Summary

This study tests if a shorter course of radiation combined with chemotherapy and an immunotherapy drug (tislelizumab) works as well as the standard longer radiation plus the same immunotherapy for people with locally advanced rectal cancer. The main goal is to see how many patients have their tumors completely disappear. About 130 adults aged 18-75 with a specific type of rectal cancer will take part.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED RECTAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Cancer Hospital

    Fuzhou, Fujian, 350014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Jinjiang Municipal Hospital

    Quanzhou, Fujian, 362200, China

    Contact Phone: •••-•••-••••

  • The Second Hospital of Longyan

    Longyan, Fujian, 364000, China

    Contact

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.